Skip to content

Medical emergency? What to do

Congress urged to act on US FDA safety reforms

3-RXPublished October 11, 20062 min read

Key points

  • Editors at a major medical journal and members of a drug-safety advisory panel joined calls on Monday for major changes to improve the U.S.
  • The IOM report pressed Congress to give the FDA more staff, funding and power -- including the ability to require the drug industry to do post-approval studies and change warning labels.
  • They also appealed for an end to "a growing politicization" of the FDA in recent years.
  • Critics said the FDA should have reacted sooner to signs of problems related to Vioxx and other medicines on the market.

Editors at a major medical journal and members of a drug-safety advisory panel joined calls on Monday for major changes to improve the U.S. Food and Drug Administration's oversight of medicines on the market.

A New England Journal of Medicine editorial urged the U.S. Congress to adopt recommendations made by an Institute of Medicine (IOM) panel last month to bolster drug safety.

The IOM report pressed Congress to give the FDA more staff, funding and power -- including the ability to require the drug industry to do post-approval studies and change warning labels.

"We face a mounting public health crisis in drug safety, and definitive action must be taken ... The IOM committee's report is a crucial starting point," the editors wrote.

They also appealed for an end to "a growing politicization" of the FDA in recent years.

Concern about side effects from prescription drugs intensified after Merck & Co Inc. withdrew arthritis drug Vioxx in September 2004 because of a link to heart damage.

Critics said the FDA should have reacted sooner to signs of problems related to Vioxx and other medicines on the market.

In another medical journal, five current or former members of the FDA's Drug Safety and Risk Management Advisory Committee also urged lawmakers to fix many of the problems the IOM and others identified.

Along with more funding for FDA drug-safety programs, the experts from outside the agency suggested a time-limited "conditional approval" for some drugs that would require additional tests.

"It is now up to Congress to take the steps necessary to reinvigorate the FDA's ability to assure the public that approved medical products are safe," Dr. Curt Furberg and others wrote in the Archives of Internal Medicine.

Congress must pass legislation next year to renew industry fees that help fund drug reviews, and that bill could be a vehicle for addressing drug safety issues.

Furberg and his co-authors backed a plan put forth in a Senate bill for a drug safety center within the FDA that would handle post-approval tracking of side effects and be separate from pre-approval drug reviews.

Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research, said on Monday such separation would "really exacerbate the problem" by making it more difficult for pre- and post-approval reviewers to work together.

"What we need is better science and more resources and mechanisms to improve the way that we work together," Galson said in an interview.

Galson and other top FDA officials previously have said they already are taking steps to strengthen drug safety monitoring and are considering the suggestions in the IOM report, which the agency requested.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.